ECSP12012357A - Análogos del glucagón - Google Patents
Análogos del glucagónInfo
- Publication number
- ECSP12012357A ECSP12012357A ECSP12012357A ECSP12012357A EC SP12012357 A ECSP12012357 A EC SP12012357A EC SP12012357 A ECSP12012357 A EC SP12012357A EC SP12012357 A ECSP12012357 A EC SP12012357A
- Authority
- EC
- Ecuador
- Prior art keywords
- glucagon
- glucagon analogs
- compounds
- glp
- diabetes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La invención proporciona materiales y procedimientos para promover la pérdida de peso o evitar el aumento de peso y para el tratamiento de la diabetes y de los trastornos metabólicos asociados. En particular, la invención proporciona novedosos compuestos peptídicos análogos al glucagón efectivos en tales procedimientos. El efecto de los compuestos puede estar mediado, por ejemplo, aumentando la selectividad por el receptor de GLP-1 en comparación con el glucagón humano.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA201000558 | 2010-06-24 | ||
US35861410P | 2010-06-25 | 2010-06-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP12012357A true ECSP12012357A (es) | 2013-01-31 |
Family
ID=44630046
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSP12012357 ECSP12012357A (es) | 2010-06-24 | 2012-12-26 | Análogos del glucagón |
Country Status (20)
Country | Link |
---|---|
US (2) | US9169310B2 (es) |
EP (1) | EP2585482B1 (es) |
JP (1) | JP6023048B2 (es) |
KR (1) | KR20130086343A (es) |
CN (1) | CN103068841A (es) |
AP (1) | AP2013006671A0 (es) |
AU (1) | AU2011269430A1 (es) |
BR (1) | BR112012033225A2 (es) |
CA (1) | CA2802897A1 (es) |
CL (1) | CL2012003641A1 (es) |
CO (1) | CO6660483A2 (es) |
EA (1) | EA201291234A1 (es) |
EC (1) | ECSP12012357A (es) |
MA (1) | MA34383B1 (es) |
MX (1) | MX2012014961A (es) |
NZ (1) | NZ604208A (es) |
PE (1) | PE20130338A1 (es) |
SG (1) | SG186764A1 (es) |
TN (1) | TN2012000560A1 (es) |
WO (1) | WO2011160633A1 (es) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0823379A2 (pt) | 2008-12-15 | 2015-07-14 | Zealand Pharma As | Análogos de glucagon |
EA020537B1 (ru) | 2008-12-15 | 2014-11-28 | Зилэнд Фарма А/С | Аналоги глюкагона |
AU2008365559B2 (en) | 2008-12-15 | 2016-02-25 | Zealand Pharma A/S | Glucagon analogues |
ES2477880T3 (es) | 2008-12-15 | 2014-07-18 | Zealand Pharma A/S | Análogos del glucagón |
US9156901B2 (en) | 2009-07-13 | 2015-10-13 | Ditte Riber | Acylated glucagon analogues |
UY33462A (es) | 2010-06-23 | 2012-01-31 | Zealand Pharma As | Analogos de glucagon |
CN103068841A (zh) | 2010-06-24 | 2013-04-24 | 西兰制药公司 | 胰高血糖素类似物 |
NZ605889A (en) | 2010-06-24 | 2014-10-31 | Takeda Pharmaceutical | Fused heterocyclic compounds as phosphodiesterases (pdes) inhibitors |
WO2013041678A1 (en) | 2011-09-23 | 2013-03-28 | Novo Nordisk A/S | Novel glucagon analogues |
SG11201407137PA (en) | 2012-05-03 | 2014-11-27 | Zealand Pharma As | Gip-glp-1 dual agonist compounds and methods |
WO2014016300A1 (en) | 2012-07-23 | 2014-01-30 | Zealand Pharma A/S | Glucagon analogues |
TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
KR20160021758A (ko) | 2013-04-18 | 2016-02-26 | 노보 노르디스크 에이/에스 | 의학용으로 사용하기 위한 안정하고 연장된 glp-1/글루카곤 수용체 코-아고니스트 |
GB201315335D0 (en) | 2013-08-29 | 2013-10-09 | Of Singapore | Amino diacids containing peptide modifiers |
BR112016008115B1 (pt) | 2013-10-17 | 2024-03-12 | Boehringer Ingelheim International Gmbh | Análogos de glucagon acilados |
US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
WO2015067715A2 (en) | 2013-11-06 | 2015-05-14 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
BR112016009995B1 (pt) | 2013-11-06 | 2023-04-18 | Zealand Pharma A/S | Compostos agonistas triplos glucagon-glp-1-gip |
AR098616A1 (es) | 2013-12-18 | 2016-06-01 | Lilly Co Eli | Péptido para el tratamiento de hipoglicemia severa |
CN106536547A (zh) | 2014-06-04 | 2017-03-22 | 诺和诺德股份有限公司 | 用于医疗用途的glp‑1/胰高血糖素受体共激动剂 |
WO2015193378A1 (en) * | 2014-06-18 | 2015-12-23 | Novo Nordisk A/S | Novel glp-1 receptor agonists with cholesterol efflux activity |
JP2017536343A (ja) * | 2014-10-10 | 2017-12-07 | ノヴォ ノルディスク アー/エス | 安定したglp−1ベースのglp−1/グルカゴン受容体コアゴニスト |
JP6898231B6 (ja) | 2014-10-29 | 2021-07-28 | ジーランド ファーマ アクティーゼルスカブ | Gipアゴニスト化合物及び方法 |
EA034820B1 (ru) | 2015-02-17 | 2020-03-25 | Эли Лилли Энд Компани | Порошковый состав для интраназального введения для лечения гипогликемии |
AU2016232218B2 (en) | 2015-03-18 | 2020-09-10 | Boehringer Ingelheim International Gmbh | Amylin analogues |
WO2016168388A2 (en) | 2015-04-14 | 2016-10-20 | Palatin Technologies, Inc. | Therapies for obesity, diabetes and related indications |
ES2763329T3 (es) | 2015-04-16 | 2020-05-28 | Zealand Pharma As | Análogo de glucagón acilado |
SI3494120T1 (sl) | 2016-08-05 | 2021-08-31 | Boehringer Ingelheim International Gmbh | Oksadiazolopiridinski derivati za uporabo kot inhibitorji grelin o-acil transferaze (GOAT) |
TWI784968B (zh) | 2016-09-09 | 2022-12-01 | 丹麥商西蘭製藥公司 | 澱粉素類似物 |
KR102502040B1 (ko) * | 2016-12-09 | 2023-02-24 | 질랜드 파마 에이/에스 | 아실화 glp-1/glp-2 이중 효능제 |
JP7211659B2 (ja) * | 2017-08-16 | 2023-01-24 | ドン-ア エスティ カンパニー リミテッド | アシル化オキシントモジュリンペプチド類似体 |
WO2019149657A1 (en) | 2018-02-02 | 2019-08-08 | Boehringer Ingelheim International Gmbh | Benzyl-, (pyridin-3-yl)methyl- or (pyridin-4-yl)methyl-substituted oxadiazolopyridine derivatives as ghrelin o-acyl transferase (goat) inhibitors |
CN111630055B (zh) | 2018-02-02 | 2023-07-14 | 勃林格殷格翰国际有限公司 | 用作饥饿素o-酰基转移酶(goat)抑制剂的吡唑取代的和吲唑取代的噁二唑并吡啶衍生物 |
CR20200331A (es) | 2018-02-02 | 2020-09-03 | Boehringer Ingelheim Int | Derivados de oxadiazolopirisdina sustituidos con heterociclilo para usar como inhibidores de ghrelin o-aciltrasferasa (goat) |
CA3087925A1 (en) | 2018-02-02 | 2019-08-08 | Boehringer Ingelheim International Gmbh | Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors |
TWI771669B (zh) | 2019-04-26 | 2022-07-21 | 美商美國禮來大藥廠 | 製備穩定胜肽調配物之方法 |
MX2022005661A (es) | 2019-11-11 | 2022-09-07 | Boehringer Ingelheim Int | Agonistas del receptor npy2. |
WO2021233882A1 (en) | 2020-05-22 | 2021-11-25 | Boehringer Ingelheim International Gmbh | Process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate |
EP4153600A1 (en) | 2020-05-22 | 2023-03-29 | Boehringer Ingelheim International GmbH | Continuous process for manufacturing alkyl 7-amino-5-methyl-[1,2,5]oxadiazolo[3,4-b]pyridine-carboxylate |
IL300239A (en) | 2020-08-07 | 2023-03-01 | Boehringer Ingelheim Int | Soluble NPY2 receptor agonists |
WO2023016346A1 (zh) * | 2021-08-10 | 2023-02-16 | 南京明德新药研发有限公司 | 含内酰胺桥的多肽化合物 |
CN115536739B (zh) * | 2022-07-04 | 2023-04-14 | 北京惠之衡生物科技有限公司 | 一种glp-1受体和gcg受体共激动多肽衍生物的制备方法 |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ202757A (en) | 1981-12-23 | 1985-11-08 | Novo Industri As | Peptides and medicaments |
HU227021B1 (en) | 1996-08-30 | 2010-05-28 | Novo Nordisk As | Glp-1 derivatives |
JP2001505872A (ja) | 1996-09-09 | 2001-05-08 | ジーランド ファーマシューティカルズ アクティーゼルスカブ | α―ヒドロキシ酸リンカーを含むペプチドプロドラッグ |
EP0929567B1 (en) | 1996-09-09 | 2005-03-02 | Zealand Pharma A/S | Solid-phase peptide synthesis |
UA65549C2 (uk) * | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
EP1066314B1 (en) | 1997-11-14 | 2007-12-26 | Amylin Pharmaceuticals, Inc. | Novel exendin agonist compounds |
CA2321026A1 (en) | 1998-03-09 | 1999-09-16 | Zealand Pharmaceuticals A/S | Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
CA2353574C (en) | 1998-12-07 | 2012-05-08 | Zheng Xin Dong | Analogues of glp-1 |
US6451987B1 (en) | 1999-03-15 | 2002-09-17 | Novo Nordisk A/S | Ion exchange chromatography of proteins and peptides |
WO2000055119A1 (en) | 1999-03-17 | 2000-09-21 | Novo Nordisk A/S | Method for acylating peptides and novel acylating agents |
EP1076066A1 (en) | 1999-07-12 | 2001-02-14 | Zealand Pharmaceuticals A/S | Peptides for lowering blood glucose levels |
GB0121709D0 (en) | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
AU2002346491A1 (en) | 2001-12-19 | 2003-07-09 | Eli Lilly And Company | Crystalline compositions for controlling blood glucose |
CA2468100A1 (en) | 2001-12-20 | 2003-07-03 | Eli Lilly And Company | Insulin molecule having protracted time action |
GB0300571D0 (en) | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
KR20050121748A (ko) | 2003-04-29 | 2005-12-27 | 일라이 릴리 앤드 캄파니 | 연장된 시간 작용을 갖는 인슐린 유사체 |
CN101155828A (zh) * | 2005-02-11 | 2008-04-02 | 安米林药品公司 | Gip类似物和具有可选择性质的杂合多肽 |
PT1891105E (pt) | 2005-06-13 | 2012-06-27 | Imp Innovations Ltd | Análogos de oxintomodulina e seus efeitos sobre o comportamento da alimentação |
WO2007024899A2 (en) | 2005-08-23 | 2007-03-01 | The General Hospital Corporation | Use of glp-1, glp-1 derivatives or glp-1 fragments for skin regeneration, stimulation of hair growth, or treatment of diabetes |
CA2628241C (en) | 2005-11-07 | 2016-02-02 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting physiological solubility and stability |
US8343914B2 (en) | 2006-01-06 | 2013-01-01 | Case Western Reserve University | Fibrillation resistant proteins |
US7928058B2 (en) | 2006-02-22 | 2011-04-19 | Merck Sharp & Dohme Corp. | Pharmaceutical composition comprising oxyntomodulin derivatives and a method for reducing body weight using the composition |
ZA200900545B (en) | 2006-07-18 | 2010-03-31 | Sanofi Aventis | Antagonist antibody against EPHA2 for the treatment of cancer |
WO2008043033A2 (en) | 2006-10-04 | 2008-04-10 | Case Western Reserve University | Fibrillation-resistant insulin and insulin analogues |
TWI428346B (zh) | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
NZ578948A (en) | 2007-02-15 | 2012-03-30 | Univ Indiana Res & Tech Corp | Glucagon/glp-1 receptor co-agonists |
EP2025684A1 (en) | 2007-08-15 | 2009-02-18 | Zealand Pharma A/S | Glucagon analogues |
DK2158214T3 (da) | 2007-06-15 | 2011-12-05 | Zealand Pharma As | Glukagonanaloger |
KR101656107B1 (ko) | 2007-11-20 | 2016-09-08 | 암브룩스, 인코포레이티드 | 변형된 인슐린 폴리펩티드 및 이의 용도 |
DE102008003566A1 (de) | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
DE102008003568A1 (de) | 2008-01-09 | 2009-07-16 | Sanofi-Aventis Deutschland Gmbh | Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil |
JP5695909B2 (ja) | 2008-01-09 | 2015-04-08 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 極度に遅延した時間作用プロファイルを有する新規なインスリン誘導体 |
CN102007143B (zh) | 2008-01-09 | 2015-08-26 | 塞诺菲-安万特德国有限公司 | 具有超延迟时效特征的新型胰岛素衍生物 |
US8993516B2 (en) | 2008-04-14 | 2015-03-31 | Case Western Reserve University | Meal-time insulin analogues of enhanced stability |
WO2009132129A2 (en) | 2008-04-22 | 2009-10-29 | Case Western Reserve University | Isoform-specific insulin analogues |
TWI451876B (zh) | 2008-06-13 | 2014-09-11 | Lilly Co Eli | 聚乙二醇化之離脯胰島素化合物 |
TWI541023B (zh) | 2008-06-17 | 2016-07-11 | 印第安納大學科技研究公司 | 在生理ph緩衝液中呈現增強之溶解度及穩定性之升糖激素類似物 |
AR072160A1 (es) | 2008-06-17 | 2010-08-11 | Univ Indiana Res & Tech Corp | Co-agonistas del receptor de glucagon/glp-1 |
PL219335B1 (pl) | 2008-07-04 | 2015-04-30 | Inst Biotechnologii I Antybiotyków | Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna |
CN102171245B (zh) | 2008-07-31 | 2015-03-25 | 卡斯西部储备大学 | 卤素稳定型胰岛素 |
BRPI0823379A2 (pt) | 2008-12-15 | 2015-07-14 | Zealand Pharma As | Análogos de glucagon |
EA020537B1 (ru) | 2008-12-15 | 2014-11-28 | Зилэнд Фарма А/С | Аналоги глюкагона |
AU2008365559B2 (en) | 2008-12-15 | 2016-02-25 | Zealand Pharma A/S | Glucagon analogues |
ES2477880T3 (es) | 2008-12-15 | 2014-07-18 | Zealand Pharma A/S | Análogos del glucagón |
CA2744558A1 (en) | 2008-12-19 | 2010-07-15 | Indiana University Research And Technology Corporation | Amide-based insulin prodrugs |
WO2010080606A1 (en) | 2008-12-19 | 2010-07-15 | Indiana University Research And Technology Corporation | Insulin analogs |
CN101519446A (zh) | 2009-03-31 | 2009-09-02 | 上海一就生物医药有限公司 | 一种重组人胰岛素及其类似物的制备方法 |
US9156901B2 (en) | 2009-07-13 | 2015-10-13 | Ditte Riber | Acylated glucagon analogues |
KR20120128129A (ko) * | 2010-01-20 | 2012-11-26 | 질랜드 파마 에이/에스 | 심장 병태의 치료 |
UY33462A (es) | 2010-06-23 | 2012-01-31 | Zealand Pharma As | Analogos de glucagon |
CN103068841A (zh) | 2010-06-24 | 2013-04-24 | 西兰制药公司 | 胰高血糖素类似物 |
US20140011733A1 (en) | 2011-01-20 | 2014-01-09 | Zealand Pharma A/S | Combination of acylated glucagon analogues with insulin analogues |
PE20142113A1 (es) | 2011-12-23 | 2014-12-03 | Zealand Pharma As | Analogos de glucagon |
TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
BR112016008115B1 (pt) | 2013-10-17 | 2024-03-12 | Boehringer Ingelheim International Gmbh | Análogos de glucagon acilados |
US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
-
2011
- 2011-06-24 CN CN2011800305165A patent/CN103068841A/zh active Pending
- 2011-06-24 SG SG2012093522A patent/SG186764A1/en unknown
- 2011-06-24 KR KR1020137001877A patent/KR20130086343A/ko not_active Application Discontinuation
- 2011-06-24 AU AU2011269430A patent/AU2011269430A1/en not_active Abandoned
- 2011-06-24 NZ NZ604208A patent/NZ604208A/en not_active IP Right Cessation
- 2011-06-24 BR BR112012033225A patent/BR112012033225A2/pt not_active IP Right Cessation
- 2011-06-24 EA EA201291234A patent/EA201291234A1/ru unknown
- 2011-06-24 EP EP11741514.1A patent/EP2585482B1/en active Active
- 2011-06-24 CA CA2802897A patent/CA2802897A1/en not_active Abandoned
- 2011-06-24 AP AP2013006671A patent/AP2013006671A0/xx unknown
- 2011-06-24 PE PE2012002452A patent/PE20130338A1/es not_active Application Discontinuation
- 2011-06-24 US US13/704,299 patent/US9169310B2/en not_active Expired - Fee Related
- 2011-06-24 WO PCT/DK2011/000072 patent/WO2011160633A1/en active Application Filing
- 2011-06-24 JP JP2013515699A patent/JP6023048B2/ja not_active Expired - Fee Related
- 2011-06-24 MA MA35571A patent/MA34383B1/fr unknown
- 2011-06-24 MX MX2012014961A patent/MX2012014961A/es not_active Application Discontinuation
-
2012
- 2012-11-29 TN TNP2012000560A patent/TN2012000560A1/en unknown
- 2012-12-21 CL CL2012003641A patent/CL2012003641A1/es unknown
- 2012-12-21 CO CO12232544A patent/CO6660483A2/es unknown
- 2012-12-26 EC ECSP12012357 patent/ECSP12012357A/es unknown
-
2015
- 2015-09-14 US US14/853,335 patent/US20150376257A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2011160633A1 (en) | 2011-12-29 |
CA2802897A1 (en) | 2011-12-29 |
JP2013530969A (ja) | 2013-08-01 |
AP2013006671A0 (en) | 2013-01-31 |
US20150376257A1 (en) | 2015-12-31 |
CL2012003641A1 (es) | 2013-09-06 |
KR20130086343A (ko) | 2013-08-01 |
SG186764A1 (en) | 2013-02-28 |
CN103068841A (zh) | 2013-04-24 |
MX2012014961A (es) | 2013-02-26 |
MA34383B1 (fr) | 2013-07-03 |
EP2585482A1 (en) | 2013-05-01 |
BR112012033225A2 (pt) | 2017-06-20 |
US20130157929A1 (en) | 2013-06-20 |
PE20130338A1 (es) | 2013-03-16 |
JP6023048B2 (ja) | 2016-11-09 |
NZ604208A (en) | 2014-10-31 |
CO6660483A2 (es) | 2013-04-30 |
TN2012000560A1 (en) | 2014-04-01 |
EP2585482B1 (en) | 2019-03-27 |
EA201291234A1 (ru) | 2013-07-30 |
US9169310B2 (en) | 2015-10-27 |
AU2011269430A1 (en) | 2013-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP12012357A (es) | Análogos del glucagón | |
ECSP12011593A (es) | Análogos de glucagón acilados | |
UY35030A (es) | Análogos de glucagón | |
UY33462A (es) | Analogos de glucagon | |
PH12016500675B1 (en) | Acylated glucagon analogues | |
MX2016004907A (es) | Analogos del glucagon. | |
CL2020002796A1 (es) | Derivados de gip y usos de estos | |
CL2014003421A1 (es) | Análogos de glucagón que exhiben actividad agonista en el receptor del péptido insulinotrópico dependiente de glusosa (gip): composición farmacéutica; y método para reducir el aumento de peso o inducir pérdida de peso, particularmente para el tratamiento de la obesidad. | |
EA201791281A1 (ru) | Соединения-коагонисты гип и гпп-1 | |
SV2017005425A (es) | Coagonistas de los receptores de glucagón y de glp-1" | |
MX2011006315A (es) | Analogos de glucagon. | |
MX2017012864A (es) | Analogo acilado del glucagon. | |
TN2011000295A1 (en) | Glucagon analogues | |
MX2011006320A (es) | Analogos de glucagon. | |
MX2011006314A (es) | Analogos de glucagon. | |
CL2012003211A1 (es) | Compuestos derivados de lactamas sustituidas con piperidinilo, moduladores de gpr119; proceso para preparar los compuestos; composicion farmaceutica que comprende a los compuestos; y uso de los compuestos en la preparacion de medicamentos para el tratamiento o prevencion de diabetes tipo 2, obesidad y condiciones relacionadas | |
CO6382136A2 (es) | Análogos de glucagón | |
ECSP15009978A (es) | Análogos de glucagón | |
CY1116448T1 (el) | Ακυλιωμενα αναλογα γλυκαγονης | |
TN2011000667A1 (en) | Acylated glucagon analogues |